v3.26.1
Segment and Geographic Information - Schedule of Segment Income of LivaNova’s Reportable Segments (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting Information [Line Items]    
Net revenue $ 362,258 $ 316,855
Cost of sales 118,509 100,601
Selling, general, and administrative 143,568 129,146
Research and development 58,695 37,879
Operating income 41,471 48,617
Operating Segments    
Segment Reporting Information [Line Items]    
Operating income 74,221 77,044
Operating Segments | Cardiopulmonary    
Segment Reporting Information [Line Items]    
Net revenue 208,655 176,320
Cost of sales 100,929 84,920
Selling, general, and administrative 59,849 53,959
Research and development 17,795 12,044
3T litigation provision 15 706
Operating income 30,067 24,691
Operating Segments | Neuromodulation    
Segment Reporting Information [Line Items]    
Net revenue 151,788 138,893
Cost of sales 14,221 13,386
Selling, general, and administrative 52,619 47,570
Research and development 40,794 25,584
3T litigation provision 0 0
Operating income $ 44,154 $ 52,353